AvalehtNTLA • NASDAQ
add
Intellia Therapeutics Inc
Viimane sulgemishind
7,36 $
Tänane vahemik
6,73 $ - 7,27 $
Aasta vahemik
5,90 $ - 28,18 $
Turuväärtus
710,13 mln USD
Keskmine maht
3,51 mln
P/E suhe
-
Dividendimäär
-
Põhibörs
NASDAQ
Uudised
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
| (USD) | dets 2024info | Y/Y muutus |
|---|---|---|
Käive | 12,87 mln | 771,57% |
Põhitegevusega seonduv kulu | 32,44 mln | 11,90% |
Puhastulu | −128,90 mln | 2,47% |
Puhaskasumimarginaal | −1,00 tuh | −114,52% |
Puhaskasum aktsia kohta | −1,27 | 13,01% |
EBITDA | −133,88 mln | 2,58% |
Tõhus maksumäär | — | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
| (USD) | dets 2024info | Y/Y muutus |
|---|---|---|
Sularaha ja lühiajalised investeeringud | 601,52 mln | −34,06% |
Kogu vara | 1,19 mld | −8,45% |
Kõik kohustused | 319,06 mln | 27,21% |
Kogu omakapital | 871,96 mln | — |
Emiteeritud aktsiate arv | 103,52 mln | — |
Hinna ja väärtuse suhe P/B | 0,86 | — |
Varade tasuvus | −28,85% | — |
Kapitali tasuvus | −31,79% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
| (USD) | dets 2024info | Y/Y muutus |
|---|---|---|
Puhastulu | −128,90 mln | 2,47% |
Põhitegevuse rahakäive | −85,20 mln | 8,45% |
Investeeringute raha | 151,56 mln | 229,93% |
Finantseerimise raha | 2,32 mln | −97,82% |
Raha ja raha ekvivalentide muutus | 68,69 mln | 15,70% |
Tasuta rahavoog | −25,54 mln | 66,88% |
Teave
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics.
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Wikipedia
Tegevjuht
Asutatud
2014
Veebisait
Töötajate arv
403
